SINT

SINTXB

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.25

+89.7% vs current

Most likely

Base case

50%

Probability

Target price

$2.20

-1.8% vs current

B-

Bear case

30%

Probability

Target price

$1.00

-55.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-22

AI commentary

This remains a low-conviction monitoring name, not a high-confidence turnaround. Primary filings support a real strategic pivot and a meaningful leadership addition, but the deterministic prior remains negative and the 10-K still centers cash runway, dilution, and commercialization uncertainty. Sentiment is therefore cautious hold/watch rather than bullish re-rate.

RankAlpha Sentiment Codex - 2026-04-22

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystQ1 2026 filing should clarify runway and ATM relianceHigh impact

The next quarterly update is the clearest near-term checkpoint because the 2025 10-K says the company is reporting substantial doubt about continuing as a going concern, had $4.1 million of cash at December 31, 2025, and still had about $6.0 million of ATM capacity available; the next filing should show whether burn is moderating or dilution risk is increasing [#10-K-2026-03-20].

2026-09-30eventNew president hire is an execution test for commercial expansionHigh impact

SINTX appointed Ryan Elmore as president effective March 16, 2026, highlighting his medical-device commercial and international experience and tying part of his equity opportunity to international business milestones; investors now need evidence that the leadership change converts into distributor wins, OEM progress, or early product commercialization traction rather than remaining purely organizational [#8-K-2026-02-18].

2026-12-31catalystFoot-and-ankle wedge commercialization must offset the planned OEM revenue step-downHigh impact

The 2025 10-K says SINTX is repositioning away from non-core low-margin OEM manufacturing toward proprietary silicon-nitride biomedical devices and notes October 2025 FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System; over the next several quarters the key question is whether this product-led strategy can produce measurable adoption and better margins before financing pressure dominates [#10-K-2026-03-20].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-22 • Updated nightlySource: Internal modelMethodology